Cargando…
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma
Multiple myeloma (MM) is an incurable hematological malignancy caused by accumulation of abnormal clonal plasma cells. Despite the recent development of novel therapies, relapse of MM eventually occurs as a result of a remaining population of drug‐resistant myeloma stem cells. Side population (SP) c...
Autores principales: | Nakagawa, Makoto, Fujita, Shuhei, Katsumoto, Takuo, Yamagata, Kazutsune, Ogawara, Yoko, Hattori, Ayuna, Kagiyama, Yuki, Honma, Daisuke, Araki, Kazushi, Inoue, Tatsuya, Kato, Ayako, Inaki, Koichiro, Wada, Chisa, Ono, Yoshimasa, Yamamoto, Masahide, Miura, Osamu, Nakashima, Yasuharu, Kitabayashi, Issay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317945/ https://www.ncbi.nlm.nih.gov/pubmed/30343511 http://dx.doi.org/10.1111/cas.13840 |
Ejemplares similares
-
CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib
por: Kagiyama, Yuki, et al.
Publicado: (2021) -
MOZ is critical for the development of MOZ/MLL fusion–induced leukemia through regulation of Hoxa9/Meis1 expression
por: Katsumoto, Takuo, et al.
Publicado: (2022) -
Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies
por: Nakagawa, Makoto, et al.
Publicado: (2018) -
Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
por: Shinohara, Haruka, et al.
Publicado: (2022) -
Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells
por: Aikawa, Yukiko, et al.
Publicado: (2015)